CN100575955C - 密蛋白的未表达作为肿瘤转移的标记物 - Google Patents

密蛋白的未表达作为肿瘤转移的标记物 Download PDF

Info

Publication number
CN100575955C
CN100575955C CN200480018784A CN200480018784A CN100575955C CN 100575955 C CN100575955 C CN 100575955C CN 200480018784 A CN200480018784 A CN 200480018784A CN 200480018784 A CN200480018784 A CN 200480018784A CN 100575955 C CN100575955 C CN 100575955C
Authority
CN
China
Prior art keywords
leu
ala
close
val
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200480018784A
Other languages
English (en)
Chinese (zh)
Other versions
CN1816745A (zh
Inventor
S·C·夸伊
崔坤元
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marina Biotech Corp
Original Assignee
MDRNA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MDRNA Inc filed Critical MDRNA Inc
Publication of CN1816745A publication Critical patent/CN1816745A/zh
Application granted granted Critical
Publication of CN100575955C publication Critical patent/CN100575955C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200480018784A 2003-04-30 2004-04-30 密蛋白的未表达作为肿瘤转移的标记物 Expired - Fee Related CN100575955C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46690503P 2003-04-30 2003-04-30
US60/466,905 2003-04-30

Publications (2)

Publication Number Publication Date
CN1816745A CN1816745A (zh) 2006-08-09
CN100575955C true CN100575955C (zh) 2009-12-30

Family

ID=33434995

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200480018784A Expired - Fee Related CN100575955C (zh) 2003-04-30 2004-04-30 密蛋白的未表达作为肿瘤转移的标记物

Country Status (8)

Country Link
US (1) US20040253211A1 (enExample)
EP (1) EP1620732A2 (enExample)
JP (1) JP2006525351A (enExample)
CN (1) CN100575955C (enExample)
CA (1) CA2523870A1 (enExample)
MX (1) MXPA05011644A (enExample)
NO (1) NO20055449L (enExample)
WO (1) WO2004098647A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP2103628A4 (en) * 2006-12-14 2012-02-22 Forerunner Pharma Res Co Ltd MONOCLONAL ANTIBODY ANTI-CLAUDIN 3, AND TREATMENT AND DIAGNOSIS OF CANCER USING SUCH ANTIBODY
WO2008114733A1 (ja) * 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗体
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
KR101741898B1 (ko) 2015-05-27 2017-06-01 울산대학교 산학협력단 Claudin 7을 포함하는 방사선 반응성 위암 진단용 바이오마커 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075177A2 (en) * 2000-04-03 2001-10-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tumor markers in ovarian cancer
CN1326947A (zh) * 2000-06-01 2001-12-19 北京双鹭药业有限责任公司 人胸腺素α原基因突变体合成、表达及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554388A (en) * 1989-02-25 1996-09-10 Danbiosyst Uk Limited Systemic drug delivery compositions comprising a polycationi substance
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
GB9522351D0 (en) * 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
WO1998000013A1 (en) * 1996-06-28 1998-01-08 The Regents Of The University Of California Enhancement of cancer cell death
DK1035833T3 (da) * 1997-12-02 2006-01-09 Archimedes Dev Ltd Sammensætning til nasal indgivelse
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6248864B1 (en) * 1997-12-31 2001-06-19 Adherex Technologies, Inc. Compounds and methods and modulating tissue permeability
WO2003069307A2 (en) * 2002-02-14 2003-08-21 The Johns Hopkins University School Of Medicine Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075177A2 (en) * 2000-04-03 2001-10-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tumor markers in ovarian cancer
CN1326947A (zh) * 2000-06-01 2001-12-19 北京双鹭药业有限责任公司 人胸腺素α原基因突变体合成、表达及应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
expression of tight junction proteins claudin-3 and claudin-4 inovarian cancer. agarwal et al.molecular biology of the cell,Vol.13 . 2002 *
large-scale serial analysis of gene expression reveals genesdofferentially expressed in ovarian cancer. hough et al.cancer research,Vol.60 No.20. 2000 *

Also Published As

Publication number Publication date
US20040253211A1 (en) 2004-12-16
JP2006525351A (ja) 2006-11-09
NO20055449L (no) 2006-01-26
NO20055449D0 (no) 2005-11-17
MXPA05011644A (es) 2005-12-15
CA2523870A1 (en) 2004-11-18
EP1620732A2 (en) 2006-02-01
CN1816745A (zh) 2006-08-09
WO2004098647A2 (en) 2004-11-18
WO2004098647A3 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
EP1382969A1 (en) Diagnosis and prevention of cancer cell invasion
US20080312093A1 (en) Method for detecting cancer and a method for suppressing cancer
EP2761300A2 (en) Recurrent gene fusions in breast cancer
JP2007518399A (ja) 肺癌を診断および治療する組成物並びに方法
KR20080080525A (ko) 유전자 전사에 대한 ｆｇｆｒ３의 억제제의 효과
CN109280704A (zh) Rasd1作为标志物在制备b-all诊断和预后评估试剂盒中的应用
Dmitrenko et al. Reduction of the transcription level of the mitochondrial genome in human glioblastoma
CN100575955C (zh) 密蛋白的未表达作为肿瘤转移的标记物
WO2004091511A2 (en) Compositions and methods to diagnose and treat lung cancer
CN107190052B (zh) Loc101928926基因的用途
EP2169077A1 (en) Methods and compositions for diagnosing an adenocarcinoma
US8067240B2 (en) Methods for the diagnosis and treatment of lung cancer
EP1354962B1 (en) Use of the slug gene or of the transcription or expression products thereof in the detection and/or treatment of cancerous cells
US7115265B1 (en) Four genetic tumor markers specific for human glioblastoma
US20070065889A1 (en) Compositions and methods to diagnose and treat lung cancer
US20210198753A1 (en) Systems and methods for determining a treatment course of action
CN106244684B (zh) 一种食管鳞癌的分子靶标
Mao et al. Cloning and functional characterization of chicken stem cell antigen 2
CN119753149A (zh) 一种抗胰腺癌靶点camk2a及其在制备胰腺癌治疗药物中的应用
Yin Molecular genetic investigations of brain tumors with neuronal differentiation
Gupta et al. Oncogenomics: Clinical pathogenesis approach
US20060110753A1 (en) Methods to diagnose and treat lung cancer
JPH11313681A (ja) 新規な癌転移マーカー

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: MALINA BIOTECHNOLOGY CO.

Free format text: FORMER NAME: NASTECH PHARM CO.

CP01 Change in the name or title of a patent holder

Address after: Washington State

Patentee after: Marina Biotech Corp

Address before: Washington State

Patentee before: Nastech Pharm Co.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20091230

Termination date: 20160430